Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,marketState,shortName,market,exchangeDataDelayedBy,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,INVVY,145000000.0,146924000,13000000,,66000000,,62000000,93000000,171000000,65000000,65000000,,-8000000,,,,4000000,201000000,136000000,30000000,1000000,,62000000,62000000,88000000.0,6000000.0,1438000000.0,233000000.0,500000000.0,1671000000.0,73000000.0,6000000.0,1460000000.0,526000000.0,-1306000000.0,192000000.0,1000000000.0,633000000.0,86000000.0,3000000.0,-1306000000.0,99000000.0,1292000000.0,178000000.0,239000000.0,93000000.0,27000000.0,-1000000,-31000000,14000000,14000000,-8000000,55000000,1000000,71000000,4000000,-2000000,-4000000,20000000,-1000000,659000000.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.095,22.007742,0.007164404,0.62,1.115,11.601886,2.0429144,0.17608468,10.3282175,3.3165827,0.3211186,2019130240,12.237489,15,America/New_York,EDT,-14400000,2,2.9019604,13.4601 - 13.6448,13.26,0.0,0.0,0,0,finmb_277824630,PRE,INDIVIOR PLC,us_market,0,PNK,False,False,13.6448,1630503461,0.38479996,13.4601,13.6448,13.4601,831,Other OTC,Indivior PLC,USD,2050,1957,7.6648,1.2817391,5.98 - 15.0,-1.3551998,-0.09034666,5.98,15.0,1469750400,-0.44,,,15.0,5.98,11.6,10.33,2.05k,1.96k,146.92M,,110.75M,0.00%,0.01%,,,,,,,,0.09,0.72%,,0.00%,"Jul 28, 2016","Jun 14, 2016",,,"Dec 30, 2020","Jun 29, 2021",19.17%,24.69%,6.94%,95.53%,725M,4.94,34.00%,555M,189M,139M,0.62,244.40%,1B,6.8,290M,124.46,2.04,1.12,115M,21M,Value,23235,Healthcare,788,9,10,"Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",North Chesterfield,804 379 1090,VA,1,1609372800,1625097600,7,United States,http://www.indivior.com,86400,10,10710 Midlothian Turnpike,Drug Manufacturers—Specialty & Generic
t-1,INVVY,104000000.0,146924000,9000000,,53000000,,80000000,87000000,148000000,52000000,52000000,,-6000000,,,,-27000000,180000000,128000000,32000000,1000000,,80000000,80000000,60000000.0,6000000.0,1447000000.0,164000000.0,523000000.0,1611000000.0,73000000.0,6000000.0,1392000000.0,521000000.0,-1307000000.0,184000000.0,945000000.0,656000000.0,81000000.0,4000000.0,-1307000000.0,100000000.0,1267000000.0,208000000.0,229000000.0,91000000.0,25000000.0,7000000,1000000,-3000000,-3000000,11000000,87000000,1000000,89000000,3000000,3000000,13000000,-28000000,-1000000,611000000.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.095,22.007742,0.007164404,0.62,1.115,11.601886,2.0429144,0.17608468,10.3282175,3.3165827,0.3211186,2019130240,12.237489,15,America/New_York,EDT,-14400000,2,2.9019604,13.4601 - 13.6448,13.26,0.0,0.0,0,0,finmb_277824630,PRE,INDIVIOR PLC,us_market,0,PNK,False,False,13.6448,1630503461,0.38479996,13.4601,13.6448,13.4601,831,Other OTC,Indivior PLC,USD,2050,1957,7.6648,1.2817391,5.98 - 15.0,-1.3551998,-0.09034666,5.98,15.0,1469750400,-0.44,,,15.0,5.98,11.6,10.33,2.05k,1.96k,146.92M,,110.75M,0.00%,0.01%,,,,,,,,0.09,0.72%,,0.00%,"Jul 28, 2016","Jun 14, 2016",,,"Dec 30, 2020","Jun 29, 2021",19.17%,24.69%,6.94%,95.53%,725M,4.94,34.00%,555M,189M,139M,0.62,244.40%,1B,6.8,290M,124.46,2.04,1.12,115M,21M,Value,23235,Healthcare,788,9,10,"Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",North Chesterfield,804 379 1090,VA,1,1609372800,1625097600,7,United States,http://www.indivior.com,86400,10,10710 Midlothian Turnpike,Drug Manufacturers—Specialty & Generic
t-2,INVVY,20000000.0,146924000,14000000,,-14000000,,-13000000,110000000,156000000,32000000,32000000,,-6000000,,,,-1000000,185000000,153000000,29000000,-46000000,,-13000000,-13000000,62000000.0,6000000.0,1449000000.0,82000000.0,459000000.0,1531000000.0,73000000.0,33000000.0,1311000000.0,577000000.0,-1308000000.0,179000000.0,858000000.0,599000000.0,75000000.0,4000000.0,-1308000000.0,103000000.0,1187000000.0,186000000.0,230000000.0,93000000.0,20000000.0,29000000,-2000000,-3000000,-3000000,-47000000,-71000000,5000000,-71000000,1000000,-5000000,-25000000,-16000000,-2000000,588000000.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.095,22.007742,0.007164404,0.62,1.115,11.601886,2.0429144,0.17608468,10.3282175,3.3165827,0.3211186,2019130240,12.237489,15,America/New_York,EDT,-14400000,2,2.9019604,13.4601 - 13.6448,13.26,0.0,0.0,0,0,finmb_277824630,PRE,INDIVIOR PLC,us_market,0,PNK,False,False,13.6448,1630503461,0.38479996,13.4601,13.6448,13.4601,831,Other OTC,Indivior PLC,USD,2050,1957,7.6648,1.2817391,5.98 - 15.0,-1.3551998,-0.09034666,5.98,15.0,1469750400,-0.44,,,15.0,5.98,11.6,10.33,2.05k,1.96k,146.92M,,110.75M,0.00%,0.01%,,,,,,,,0.09,0.72%,,0.00%,"Jul 28, 2016","Jun 14, 2016",,,"Dec 30, 2020","Jun 29, 2021",19.17%,24.69%,6.94%,95.53%,725M,4.94,34.00%,555M,189M,139M,0.62,244.40%,1B,6.8,290M,124.46,2.04,1.12,115M,21M,Value,23235,Healthcare,788,9,10,"Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",North Chesterfield,804 379 1090,VA,1,1609372800,1625097600,7,United States,http://www.indivior.com,86400,10,10710 Midlothian Turnpike,Drug Manufacturers—Specialty & Generic
t-3,INVVY,18000000.0,146924000,8000000,,13000000,,10000000,93000000,131000000,30000000,30000000,,-6000000,,,,3000000,159000000,129000000,28000000,-17000000,,10000000,10000000,62000000.0,6000000.0,1467000000.0,80000000.0,535000000.0,1547000000.0,73000000.0,,1324000000.0,535000000.0,-1323000000.0,186000000.0,929000000.0,659000000.0,58000000.0,4000000.0,-1323000000.0,97000000.0,1202000000.0,187000000.0,231000000.0,86000000.0,27000000.0,7000000,-2000000,-3000000,-3000000,5000000,21000000,5000000,26000000,6000000,9000000,-6000000,-5000000,-2000000,543000000.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.095,22.007742,0.007164404,0.62,1.115,11.601886,2.0429144,0.17608468,10.3282175,3.3165827,0.3211186,2019130240,12.237489,15,America/New_York,EDT,-14400000,2,2.9019604,13.4601 - 13.6448,13.26,0.0,0.0,0,0,finmb_277824630,PRE,INDIVIOR PLC,us_market,0,PNK,False,False,13.6448,1630503461,0.38479996,13.4601,13.6448,13.4601,831,Other OTC,Indivior PLC,USD,2050,1957,7.6648,1.2817391,5.98 - 15.0,-1.3551998,-0.09034666,5.98,15.0,1469750400,-0.44,,,15.0,5.98,11.6,10.33,2.05k,1.96k,146.92M,,110.75M,0.00%,0.01%,,,,,,,,0.09,0.72%,,0.00%,"Jul 28, 2016","Jun 14, 2016",,,"Dec 30, 2020","Jun 29, 2021",19.17%,24.69%,6.94%,95.53%,725M,4.94,34.00%,555M,189M,139M,0.62,244.40%,1B,6.8,290M,124.46,2.04,1.12,115M,21M,Value,23235,Healthcare,788,9,10,"Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.",North Chesterfield,804 379 1090,VA,1,1609372800,1625097600,7,United States,http://www.indivior.com,86400,10,10710 Midlothian Turnpike,Drug Manufacturers—Specialty & Generic
